Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brexit

Set Alert for Brexit

Five Themes For BIO-Europe 2017

From BIO-Europe, the biggest pharma and biotech partnering meeting in Europe, Scrip lists the five hottest topics of discussion and debate.

Brexit Business Strategies Research and Development Strategies

Brexit Ambiguity A Top Priority For Bayer's New UK & Ireland CEO

Lars Bruening, who recently succeeded Alexander Moscho as Bayer's CEO for the UK and Ireland, talks to Scrip about Brexit uncertainties and fostering the right dialog between pharma and healthcare systems.

Brexit Business Strategies Market Access

Latest From Brexit

Pharma Retains Brexit Premium Skepticism

Scrip and IQVia explore how Brexit will impact clinical trials, product launches and funding in the UK.

Brexit Business Strategies

2017 – Scrip Readers’ Pharma Year In Review

As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.

Brexit Commercial

What Does 2018 Hold For Biopharma?

From ongoing progress in IO to revolutions in AI, and from pricing headaches to new therapies for migraine: Scrip has gleaned from experts and industry executives their expectations and predictions for 2018's hot topics. Here is our digest.

Commercial Strategy

UK Life Science 'Needs Manufacturing Incentives, NHS Access' After Brexit

MSD's R&D head Roger Perlmutter and Sir John Bell tell Scrip the UK government needs to offer better manufacturing incentives to the life science sector and also encourage more efficient drug innovation there.

Brexit Business Strategies

Time Is Running Out For Industry To Prepare For Brexit, Firms Begin to Feel Staffing Effects

Nearly 18 months after the UK voted to leave the European Union, pharmaceutical companies and regulators are still in the dark as to what kind of regulatory arrangements will exist between the two parties after Brexit takes place in March 2019.

Scrip 100 Brexit

Pharma Lauds Brexit ‘Breakthrough’ But Says Focus Now Must Be On Drug Regulation & Supply

The UK pharmaceutical industry has welcomed the announcement that Brexit talks are to move on to trade deal discussions, but says a regulatory cooperation agreement and a fixed transition period are essential to safeguard European supply chains. Several pharma executives outlined some of their key concerns at a parliamentary committee hearing on Dec. 5.

Brexit Europe
See All
UsernamePublicRestriction

Register